Vnitr Lek 2005, 51(2):157-162

Vyšetření aktivity destičkových funkcí se vztahem k rezistenci na kyselinu acetylsalicylovou - editorial

J. Malý
II. interní klinika Lékařské fakulty UK a FN, Hradec Králové, přednosta prof. MUDr. Jaroslav Malý, CSc.

Received: January 1, 2005; Published: February 1, 2005  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Malý J. Vyšetření aktivity destičkových funkcí se vztahem k rezistenci na kyselinu acetylsalicylovou - editorial. Vnitr Lek. 2005;51(2):157-162.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Schwartz KA, Schwartz DE, Davis JA. Detection and monitoring of aspirin inhibition of platelet function using the cationtic propyl gallate platelet aggregation assay. In: Abstract Book American Society of Hematology Meeting, 1998: 17-19. Go to PubMed...
    2. Kottke-Marchant K, Corcoran G. The Laboratory Diagnosis of Platelet Disorders. An Algorithmic Approach. Arch Pathol Labor Med 2001; 126: 133-146. Go to original source...
    3. Maree AO, Fitzgerald DJ. Aspirin and coronary artery disease. Thromb Haemost 2004; 92: 1175-1181. Go to original source... Go to PubMed...
    4. Bhatt DL. Aspirin resistance: more than just a laborotary curiosity. JACC 2004; 43: 1127-1129. Go to original source... Go to PubMed...
    5. Gum PA, Kottke-Marchant K, Welsh PA et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 19: 961-965. Go to original source... Go to PubMed...
    6. Antithrombotics Trialist's Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patiens. BMJ 1999; 318: 759-764. Go to PubMed...
    7. Chen WH, Lee PY, Ng W et al. Aspirin resistance in associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despote clopidrogel pretreatment. J Am Coll Cardiol 2004; 43: 1122-1126. Go to original source... Go to PubMed...
    8. Eikelboom JW, Hirsh J, Weitz JI et al. Aspirin resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-1655. Go to original source... Go to PubMed...
    9. Hankey GJ, Eikelboom JW. Aspirin resistance. BMJ 2004; 328: 477-479. Go to original source... Go to PubMed...
    10. Kurth T, Glynn RJ, Walker AM et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal intiinflamatory drugs. Circulation 2003; 108: 1191-1195. Go to original source... Go to PubMed...
    11. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361: 572-574. Go to original source... Go to PubMed...
    12. Mason PJ, Freedman JE, Jacobs AK Aspirin resistance: current concepts. Rev Cardiovasc Med 2004; 53: 156-163.
    13. Malý J, Pecka M, Dulíček P et al. Vyšetření aktivity destiček se vztahem k resistenci na kyselinu acetylsalicylovou. Sborník XI. Slovensko-České konference o hemostáze a trombóze. Bratislava: Universita Komenského 2004: 26-29.
    14. Pecka M, Gregor J, Urbánková J et al. Use of propyl gallate in monitoring of antiaggregation therapy with ASA in patients with cardiovascular syndrome. In: Cocheri S, Gensini G, Palareti G, Prisce D, Monduzzi D (eds). Reports from the 17th International Congress on Thrombosis 2002: 15-18.
    15. Stejskal D et al. Vyšetření aktivity (viz titul). Vnitř Lék 2004; 50 (8): 591-599. Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.